|
The following are publications relating to iron overload and iron chelation therapy.
2008 | Curr Opin Hematol
Iron regulation and erythropoiesis. (Nemeth E.)
2008 | Cancer
Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. (Jabbour E. et al.)
2008 | Leuk Res
Iron overload in myelodysplastic syndromes: A Canadian consensus guideline.; (Wells R.A. et al.)
2008 | National Comprehensive Cancer Network
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology – v2: Myelodysplastic Syndromes
2008 | Pediatr Blood Cancer
Liver biopsy results in patients with sickle cell disease on chronic transfusions: Poor correlation with ferritin levels. (Karam L.B. et al.)
2007 | Ann Hematol
Early clinical impact of iron overload in stem cell transplantation. A prospective study. (Altes A. et al.)
2007 | Am J Hematol
Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multicenter study of iron overload. (Fung E.B. et al.)
2007 | Blood
Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. (Armand P. et al.)
2007 | Curr Opin Hematol
Magnetic resonance imaging measurement of iron overload. (Wood J.C.)
2007 | Eur J Haematol
Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. (Takatoku M. et al.)
2007 | Thalassemia International Federation.
Guidelines for the clinical management of thalassemia 2nd Edition,
2005 | Ann N Y Acad Sci
Survival and complications in thalassemia. (Borgna-Pignatti C. et al.)
2005 | Best Pract Res Clin Haematol
LPI-labile plasma iron in iron overload. (Cabantchik Z.I. et al.)
2005 | Blood
Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. (St Pierre T.G. et al.)
2005 | Hematol Oncol Clin North Am
Iron overload in myelodysplastic syndromes. (Gattermann N. et al.)
2005 | J Clin Oncol
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. (Malcovati L. et al.)
2005 | N Engl J Med
Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. (Adams R.J. et al).
2004 | Br J Haematol
Evaluation of iron overload. (Jensen P.D.)
2004 | Curr Opin Hematol
Hepcidin in iron metabolism. (Ganz T.)
2004 | Science
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. (Nemeth E. et al.)
2001 | Eur Heart J
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. (Anderson L.J. et al.)
2003 | Br J Haematol
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. (Bowen D. et al.)
2002 | Haematologica
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. (Alessandrino E.P. et al.)
2002 | National Heart, Lung and Blood Institute.
The management of sickle cell disease,
2001 | Semin Hematol
Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. (Ballas S.K.)
2000 | Lancet
Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. (Modell B. et al.)
2000 | N Engl J Med
Hepatic iron concentration and total body iron stores in thalassemia major. (Angelucci E et al.)
1999 | N Engl J Med
Disorders of iron metabolism. (Andrews N.C.)
1998 | Ann NY Acad Sci
Pathophysiology of iron overload. (Hershko C. et al.).
1998 | N Engl J Med
Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. (Adams R.J. et al.).
1995 | Haematologica
Thalassemia intermedia. (Camaschella C. et al.)
1994 | N Engl J Med
Survival in medically treated patients with homozygous beta-thalassemia. (Olivieri N.F. et al.)
2008 | Blood
Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. (Cohen A.R. et al.)
2008 | J Cardiovasc Magn Reson
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. (Tanner M.A. et al.)
2008 | Acta Haematol
Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. substudy of a randomized open-label phase II trial. (Vichinsky E. et al.)
2008 | Curr Med Res Opin
Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. (Karnon J. et al.)
2008 | Eur J Haematol
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. (Porter J. et al.)
2007 | Br J Haematol
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. (Vichinsky E. et al.)
2007 | Circulation
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. (Tanner M.A. et al.)
2007 | Clin Ther
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. (Cappellini M.D. et al.)
2006 | Blood
Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. (Glickstein H. et al.)
2006 | Blood
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. (Cappellini M.D. et al.)
2006 | Blood
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. (Pennell D. et al.)
2006 | Haematologica
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. (Galanello R. et al.)
2006 | Transl Res
Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. (Wood J.C. et al.)
2003 | Blood
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. (Cohen A.R. et al.)
2000 | Blood
Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. (Davis B.A. et al.)
1996 | Acta Haematologica
Results of long-term iron-chelating therapy. (Gabutti V. et al.)
1994 | N Engl J Med
Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. (Brittenham G.M. et al.)
1992 | Br J Haematol
Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. (Jensen P.D. et al.)
|
